middle.news
How Recce’s Synthetic Antibiotic RECCE 327 Could Transform Infection Treatment by 2026
11:02am on Thursday 19th of March, 2026 AEDT
•
Healthcare
Read Story
How Recce’s Synthetic Antibiotic RECCE 327 Could Transform Infection Treatment by 2026
11:02am on Thursday 19th of March, 2026 AEDT
Key Points
Phase 3 trial underway in Indonesia with 155 patients enrolled
RECCE 327 targets broad-spectrum, multidrug-resistant bacterial infections
Strategic partnership with Indonesian biotech PT Etana to accelerate regional development
Qualified Infectious Disease Product designation by the US FDA grants market exclusivity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE